AI in Drug Discovery

You’re invited – AI in Drug Discovery, Merck KGaA, Darmstadt, Germany Panel Discussion and Drinks Reception Wednesday 17 September 4pm Advances in artificial intelligence are revolutionising the pharmaceutical industry, offering unprecedented opportunities for innovation in drug discovery and design. This is a timely event that will examine the key challenges and opportunities of advanced artificial intelligence and quantum technologies in drug design and discovery. Featured panellists Kenneth Mulvany, Executive Chairman, BenevolentAI Thomas Clozel, Co-founder and CEO, Owkin Sabrina Maniscalco, CEO, Algorithmiq Tim Guilliams, Co-founder and CEO, Healx Stef van Grieken, Co-founder and CEO, Cradle Key topics for discussion: The role of AI in protein design and protein structure prediction; The AI driven drug discovery process; How can AI help predict the dynamic behaviour of proteins; Personalised medicine and precision drug design; Ethics and regulation in AI-driven drug discovery; How academic research, pharmaceutical companies, and AI start-ups can collaborate to accelerate the adoption of AI in drug discovery; Quantum Computing and AI: Exploring how advances in quantum computing could further revolutionise protein design and protein folding predictions and drug discovery. Tickets and event schedule:  Don’t miss the opportunity to engage in thought-provoking discussions, and network with technology leaders and influential investors, exploring the role AI will play in shaping healthcare, over drinks and canapes.